[HTML][HTML] A comparative analysis of paediatric dose-finding trials of molecularly targeted agent with adults' trials
… study of erlotinib followed by the combination of erlotinib and temozolomide: a Children’s
Oncology Group Phase I Consortium Study … pediatric phase I study of erlotinib in brainstem …
Oncology Group Phase I Consortium Study … pediatric phase I study of erlotinib in brainstem …
Axl mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib
… and characterized an erlotinib-resistant HNC cell line (HN5-ER) to investigate the
molecular mechanisms associated with erlotinib resistance in HNC. We show that erlotinib-resistant …
molecular mechanisms associated with erlotinib resistance in HNC. We show that erlotinib-resistant …
[HTML][HTML] Gemcitabine combined with capecitabine compared to gemcitabine with or without erlotinib as first-line chemotherapy in patients with advanced pancreatic …
JY Lim, JH Cho, SJ Lee, DK Lee… - Cancer research and …, 2015 - ncbi.nlm.nih.gov
… for pancreas cancer has not been studied thus far. The aim of this study is to retrospectively
compare the efficacy and toxicity of capecitabine or erlotinib in combination with gemcitabine …
compare the efficacy and toxicity of capecitabine or erlotinib in combination with gemcitabine …
Effect of food on the pharmacokinetics of erlotinib, an orally active epidermal growth factor receptor tyrosine-kinase inhibitor, in healthy individuals
J Ling, S Fettner, BL Lum, M Riek, A Rakhit - Anti-cancer drugs, 2008 - journals.lww.com
… indicate that food can substantially increase plasma exposure to erlotinib. Given the maximum
tolerated dose of erlotinib used in clinical practice, we recommend that erlotinib be taken …
tolerated dose of erlotinib used in clinical practice, we recommend that erlotinib be taken …
[HTML][HTML] Maintenance erlotinib improves clinical outcomes of unresectable advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials
… The aim of this study was to evaluate the efficacy and safety of erlotinib as maintenance …
Six eligible studies including 4,372 patients were analyzed. Erlotinib was administered to 2,191 …
Six eligible studies including 4,372 patients were analyzed. Erlotinib was administered to 2,191 …
Nicotine induces resistance to erlotinib therapy in non-small-cell lung cancer cells treated with serum from human patients
T Imabayashi, J Uchino, H Osoreda, K Tanimura… - Cancers, 2019 - mdpi.com
… Although both components are considered to contribute to the resistance to EGFR-TKI, further
investigation with a comparative study on which components contribute the most needs to …
investigation with a comparative study on which components contribute the most needs to …
RELAY subgroup analyses by EGFR Ex19del and Ex21L858R mutations for ramucirumab plus erlotinib in metastatic non–small cell lung cancer
…, M Reck, RELAY study investigators - Clinical Cancer …, 2021 - AACR
… -line treatment of EGFRm NSCLC, ramucirumab plus erlotinib (RAM+ERL) showed a consistent
PFS treatment benefit compared with placebo plus erlotinib (PBO+ERL) among patients …
PFS treatment benefit compared with placebo plus erlotinib (PBO+ERL) among patients …
Prediction of sensitivity to gefitinib/erlotinib for EGFR mutations in NSCLC based on structural interaction fingerprints and multilinear principal component analysis
… The third limitation is that the method used in this study may be not suitable for irreversible
TKIs, … In this study, 1M17 (EGFR WT-erlotinib complex) was chosen and the main part of the …
TKIs, … In this study, 1M17 (EGFR WT-erlotinib complex) was chosen and the main part of the …
Influence of rutin, sinapic acid, and naringenin on binding of tyrosine kinase inhibitor erlotinib to bovine serum albumin using analytical techniques along with …
… This study evaluated the interactions of rutin (RUT), naringenin (NAR), and sinapic acid (SIN…
the anticancer drug, the tyrosine kinase inhibitor Erlotinib (ETB), using various analytical …
the anticancer drug, the tyrosine kinase inhibitor Erlotinib (ETB), using various analytical …
RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure–response relationship
K Nakagawa, EB Garon, L Gao, S Callies… - Cancer chemotherapy …, 2022 - Springer
… Observed exposure parameters for erlotinib are shown in Online Resource 2. Erlotinib PK
… Distribution of erlotinib exposure parameters in plasma were generally similar between the …
… Distribution of erlotinib exposure parameters in plasma were generally similar between the …